On July 30, JOINN fell 5.34% in regular trading, trading at HK$22.28/share, with turnover of HK$47.99 million.

The decline was driven by broad weakness across the Life Sciences Tools & Services sector, with WUXI BIO down 4.37%, INSILICO down 3.72%, WUXI APPTEC down 3.22%, and GENSCRIPT BIO down 2.87%, reflecting widespread selling pressure across the industry.

Market concerns over the company's earnings quality continued to weigh on sentiment. The company's first-half profit surge was primarily attributable to approximately RMB 703 million to 777 million in fair value changes from experimental monkey biological assets, while core laboratory service operations posted net profit of only negative RMB 142 million to RMB 64.97 million, indicating that the main business has yet to achieve meaningful profitability recovery. Additionally, profit-taking pressure persisted following significant prior price volatility, with the stock having experienced a limit-up session on July 27 followed by an 8.31% decline on July 28.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)